Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration

Diabetes Care

Volumn 23, Issue 6, 2000, Pages 779-785

  Weyer, Christian ^a,b   Tataranni, P Antonio ^a   Pratley, Richard E ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5A [DEARGININE]; INSULIN;

ADULT; ARTICLE; BODY FAT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE METABOLISM; HUMAN; HUMAN EXPERIMENT; INSULINEMIA; MALE; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST;

EID: 0034043472     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.23.6.779     Document Type: Article

References (35)

1. Mohammed-Ali V, Pinkey JH, Coppack SW: Adipose tissue as an endocrine and paracrine organ. Int J Obes 22:1145-1158, 1998
2. Sniderman AD, Cianflone K: The adipsin-acylation stimulating protein pathway and microenvironmental metabolic regulation. In Genetic Variation and Dietary Response. World Rev Nutr Diet. Simopoulos AP, Ed. Basel, Karger, 1997, p. 44-81
3. Maslowska MH, Sniderman AD, Germinario R, Cianflone K: ASP stimulates glucose transport in cultured human adipocytes. Int J Obes 21:261-266, 1997
4. Germinario R, Sniderman AD, Manuel S, Lefebvre SP, Baldo A, Cianflone K: Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation stimulating protein. Metabolism 40:574-580, 1993
5. Tao YZ, Cianflone K, Sniderman AD, Colby-Germinario SP, Germinario RJ: Acylation-stimulating protein (ASP) regulates glucose transport in the rat L6 muscle cell line. Biochem Biophys Acta 1344:221-229, 1997
6. Murray I, Sniderman AD, Cianflone K: Enhanced triglyceride clearance with intraperitoneal human acylation-stimulating protein in C57BL/6 mice. Am J Physiol 277:E474-E480, 1999
7. Sniderman AD, Cianflone K, Eckel RH: Levels of acylation stimulating protein in obese women before and after moderate weight loss. Int J Obes 15:333-336, 1991
8. Weyer C, Pratley RE: Fasting and post-prandial plasma concentrations of acylation-stimulating protein (ASP) in lean and obese Pima Indians compared to Caucasians. Obes Res 7:444-452, 1999
9. Cianflone K, Zhang XJ, Genest J, Sniderman AD: Plasma acylation stimulating protein in coronary artery disease. Arterioscler Thromb Vasc Biol 17:1239-1244, 1997
10. Maslowska M, Vu H, Phelis S, Sniderman AD, Rhode BM, Blank D, Cianflone K: Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Invest 29:679-686, 1999
11. Cianflone K, Maslowska M, Sniderman AD: Impaired response of fibroblasts in patients with hyperapobetalipoproteinemia to acylation stimulating protein. J Clin Invest 85: 722-730, 1990
12. Pomeroy C, Mitchell J, Eckert E, Raymond N, Crosby R, Dalmasso AP: Effect of body weight and calorie restriction on plasma complement proteins, including factor D/adipsin: studies in anorexia nervosa and obesity. Clin Exp Immunol 108:507-515, 1997
13. Mantov S, Raev D: Additive effects of diabetes and systemic hypertension on the immune mechanisms of atherosclerosis. Int J Cardiol 56:145-148, 1996
14. Figueredo A, Ibarra JL, Bagazgoitia J, Rodriguez A, Molino AM, Fernandez-Cruz A, Patino R: Plasma C3d levels and ischemic heart disease in type II diabetes. Diabetes Care 16:445-449, 1993
15. Ylitalo K, Porkka KVK, Meri S, Nuotio I, Suurinkeroinen E, Vakkilainen J, Pajukanta P, Viikari JSA, Peltonen L, Ehnholm C, Taskinen MR: Serum complement and familial combined hyperlipidemia. Atherosclerosis 129:271-277, 1997
16. Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Volta U, Puddu GM, Puddu P: Relationship between serum C3 levels and traditional risk factors for myocardial infarction. Acta Cardiol 53:345-354, 1998
17. Muscari A, Bozzoli C, Puddu GM, Sangiorgi Z, Dormi A, Rovinetti A, Descovich GC, Puddu P: Association of serum C3 levels with the risk of myocardial infarction. Am J Med 98:357-361, 1995
18. Hansson GK, Jonasson L, Seifert PS, Stemme S: Immune mechanisms in atherosclerosis. Arteriosclerosis 9:567-578, 1989
19. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286-1292, 1997
20. Pickup JC, Crook MA: Is type 2 diabetes mellitus a disease of the innate immune system? Diabetologia 41:1241-1248, 1998
21. Fernandez-Real JM, Ricard W: Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 42:1367-1374, 1999
22. Reaven GM: Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
23. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194, 1991
24. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794, 1999
25. Tataranni PA, Ravussin E: Use of dual-energy X-ray absorptiometry in obese individuals. Am J Clin Nutr 62:730-734, 1995
26. Hotamisligil GS, Spiegelman BM: Tumor necrosis factor-α: a key component of the obesity-diabetes link. Diabetes 43:1271-1278, 1994
27. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 95:2409-2415, 1995
28. Winkler G, Salamon F, Harmos G, Salamon D, Speer G, Szekeres O, Hajos P, Kovacs M, Simon K, Cseh K: Elevated serum tumor necrosis factor-alpha concentrations and bioactivity in type 2 diabetics and patients with android type obesity. Diabetes Res Clin Pract 42:169-174, 1998
29. Kado S, Nagase T, Nagata N: Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol 36:67-72, 1999
30. Colten HR, Strunk RC: Synthesis of complement components in liver and extrahepatic sites. In Complement in Health and Disease. Whaly K, Loos M, Weiler JM, Eds. Vol. 20. Dordrecht, the Netherlands, Kluwer Academic, 1993, p. 127
31. Strunk RC, Tashjian AH Jr, Colten HR: Complement biosynthesis in vitro by rat hepatoma cell strains. J Immunol 114:331-335, 1975
32. Maslowska M, Scantlebury I, Germinario R, Cianflone K: Acute in vitro production of ASP in differentiated adipocytes. J Lipid Res 38:21-31, 1997
33. Campos SP, Baumann H: Insulin is a prominent modulator of the cytokine-stimulated expression of acute-phase plasma protein genes. Mol Cell Biol 12: 1789-1797, 1992
34. Yokota T, Hansson GK: Immunological mechanisms in atherosclerosis. J Intern Med 238:479-489, 1995
35. Muscari A, Massarelli G, Bastagli L, Poggiopollini G, Tomassetti V, Drago G, Martignali C, Pacilli P, Boni P, Puddu P: Relationship of serum C3 to fasting insulin and traditional risk factors in 1090 middle aged men (Abstract). Eur Heart J 20:178, 1999